huMNC2-CAR with secreted factor to increase persistence

N/A

Report date: 2024/11/04 15:26:22

Base Information

Drug NamehuMNC2-CAR with secreted factor to increase persistence

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-MUC1

TargetsMucin-1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMinerva Biotechnologies

China Registration ClassN/A

Develop Information

Active CompaniesMinerva Biotechnologies

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A